Structure and signifi cance of cytogenetic abnormalities in patients with multiple myeloma

Introduction. Cytogenetic and genomic traits of tumour cells are considered the key mediating factors in multiple myeloma (MM). Selected chromosomal abnormalities are prognostic of therapeutic response and patient survival in MM.

Aim — to assess of the diversity and rate of chromosomal abnormalities in MM patients and their association with the disease course.

Materials and methods. The study enrolled 134 MM patients with pre-treatment bone marrow FISH assay screening for chromosomal abnormalities: t(11;14), t(4;14), t(14;16), t(14;20), t(6;14), hyperdiploidy, del13q14/-13, del17p13/TP53, amp1q21, t(8q24)/cMYC. The studied criteria at the MM onset were: hemogram, lactate dehydrogenase (LDH) activity, calcium, β2-microglobulin and creatinine concentrations, punctate cytology, bone marrow trephine biopsy and/or soft tissue biopsy histology, bone X-ray, immunochemical variant of MM, disease staging. A median follow-up was 20 months (3.2–77.4).

Results. The primary chromosomal abnormality rate was 82.9  %, among them t(14q32)/IGH  — 29.1  %, multiple trisomies — 46.3 % and their combination — 7.5 %. The rates of particular t(14q32)/IGH): t(11;14) — 16.4 %, t(4;14) — 12.7 %, t(14;16) and t(14;20) — 3.7 and 2.2 %, respectively. The secondary chromosomal abnormality rate was 69.4 %, among them del13q14/-13 — 40.3 %, amp1q21 — 39.6 %, t(8q24)/cMYC — 17.2 %, del17p13/TP53 — 12.7 %, del1p32 — 2.2 %. Analyses of the primary–secondary abnormality combinations showed that del13q14/-13 is more frequently combined with t(4;14) and less frequently with trisomies (p < 0.05). Amp1q21 occurs more frequently with t(4;14) and less — with t(11;14) (p<0.05). Patients with t(4;14) more frequently (p < 0.05) had anemia at a hemoglobin level<100 g/L, and the presence of amp1q21 and del17p13/TP53-enhanced serum LDH activity (p < 0.05). Abnormality t(8q24)/cMYC more often co-occurred with higher serum β2-microglobulin concentrations (p < 0.05). A three-year overall survival (OS) in del17p13/TP53-positive patients was 35.5 vs. 71.3 % in the negative (p = 0.002) and 50.8 vs. 67 % — in t(8q24)/cMYC-positive and negative patients, respectively (p = 0.001). Patients without amp1q21, with one, with two or more additional 1q21 copies had a five-year OS 79.4, 67.3 and 20.9 %, respectively (p = 0.0016), and a two-year progression-free survival (PFS) 83, 50 and 0 %, respectively (p = 0.005).

Conclusion. We establish a negative impact of del17p13/TP53 and t(8q24)/cMYC on patients’ OS in MM, as well as unfavourable effect of amp1q21 on OS and PFS in the presence of two or more additional copies of 1q21 loci.

1. Fonseca R., Debes-Marun C.S., Picken E.B., et al. The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood. 2003; 102(7): 2562–7. DOI: 10.1182/blood-2003-02-0493.

2. Smadja N.V., Fruchart C., Isnard F., et al. Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases. Leukemia. 1998; 12(6): 960–9. DOI: 10.1038/sj.leu.2401041.

3. Wuilleme S., Robillard N., Lode L., et al. Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma. Leukemia. 2005; 19(2): 275–8. DOI: 10.1038/sj.leu.2403586.

4. Avet-Loiseau H., Attal М., Campion L., et al. Longterm analysis of the IFM 99 trials for myeloma: Cytogenetic abnormalities (t(4;14), del(17p), 1q gains) play a major role in defining long-term survival. J Clin Oncol. 2012; 30(16): 1949–52. DOI: 10.1200/JCO.2011.36.5726.

5. Mikhael J.R., Dingli D., Roy V., et al. Management of newly diagnosed symptomatic multiple myeloma: Updated Mayo Stratification of Myeloma and RiskAdapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc. 2013; 88(4): 360–76. DOI: 10.1016/j.mayocp.2013.01.019.

6. Ross F.M., Chiecchio L., Dagrada G., et al. The t(14;20) is a poor prognostic factor in myeloma but is associated with long term stable disease in MGUS. Haematologica. 2010; 95(7): 1221–5. DOI: 10.3324/haematol.2009.016329.

7. Palumbo A., Avet-Loiseau H., Oliva S., et al. Revised International Staging System for Multiple Myeloma: A report from International Myeloma Working Group. J Clin Oncol. 2015; 33(26): 2863–9. DOI: 10.1200/JCO.2015.61.2267.

8. An G., Xu Y., Shi L., et al. Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no prognostic value. Haematologica. 2014; 99(2): 353–9. DOI: 10.3324/haematol.2013.088211.

9. Avet-Louseau H., Daviet A., Sauner S., Bataille R. Intergroupe Francophone du Myélome. Chromosome 13 abnormalities in multiple myeloma are mostly monosomy 13. Br J Haematol. 2000; 111(4): 1116–7. DOI: 10.1046/j.1365-2141.2000.02488.x.

10. Fonseca R., Oken M.M., Harrington D., et al. Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q-arm or monosomy. Leukemia. 2001; 15(6): 981–6.

11. Neben K., Lokhorst H.M., Jauch A., et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood. 2012; 119(4): 940–8. DOI: 10.1182/blood-2011-09-379164.

12. Avet-Loiseau H., Gerson F., Magrangeas F., et al. Rearrangements of the cmyc oncogene are present in 15 % of primary human multiple myeloma tumors. Blood. 2001; 98(10): 3082–6. DOI: 10.1182/blood.v98.10.3082.

13. Jagannath S., Richardson P.G., Sonneveld P., et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia. 2007; 21(1): 151–7. DOI: 10.1038/sj.leu.2404442.

14. Avet-Loiseau H., Leleu X., Roussel M., et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol. 2010; 28(30): 4630–4. DOI: 10.1200/JCO.2010.28.3945.

15. Hanamura I., Stewart J.P., Huang Y., et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: Incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantations. Blood. 2006; 108(5): 1724–32. DOI: 10.1182/blood-2006-03-009910.

16. Nemec P., Zemanova Z., Greslikova H., et al. Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with highdose chemotherapy. Biol Blood Marrow Transplant. 2010; 16(4): 548–54. DOI: 10.1016/j.bbmt.2009.11.025.

17. Rajkumar S.V., Dimopoulos M.A., Palumbo A., et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014; 15(12): 538–48. DOI: 10.1016/S1470-2045(14)70442-5.

18. Durie B.G., Salmon S.E. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer. 1975; 36(3): 842–54.

19. Greipp P.R., San Miguel J., Durie B.G., et al. International staging system for multiple myeloma. J Clin Oncol. 2005; 23(15): 3412–20. DOI: 10.1200/JCO.2005.04.242.

20. Miltenyi Biotec; 2020. http://www.miltenyibiotec.com.

21. Simons A., Shaffer L.G., Hastings R.J. Cytogenetic nomenclature: Changes in the ISCN 2013 compared to the 2009 edition. Cytogenet Genome Res. 2013; 141: 1–6. DOI: 10.1159/000353118.

22. Mendeleeva L.P., Votyakova О.М., Pokrovskaya О.S., et al. National clinical recommendations on diagnosis and treatment of multiple myeloma. Gematologiya i transfusiologiya. 2016; 61(1-S2): 1–24. DOI: 10.18821/0234-5730-2016-61-1 (In Russian).

23. Kumar S., Fonseca R., Ketterling R.P., et al. Trisomies in multiple myeloma: Impact on survival in patients with high-risk cytogenetics. Blood. 2012; 119(9): 2100–5. DOI: 10.1182/blood-2011-11-390658. Correction in: Blood. 2014; 123(10): 1621. DOI: 10.1182/blood-2014-01-552653.

24. Walker B.A., Wardell C.P., Murison A., et al. APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nature Commun. 2015; 6: 1–11. DOI: 10.1038/ncomms7997.

25. Avet-Loiseau H., Malard F., Campion L., et al. Translocation t(14;16) and multiple myeloma: Is it really an independent prognostic factor? Blood. 2011; 117(6): 2009–11. DOI: 10.1182/blood-2010-07-295105.

26. Chretien M.L., Corre J., Lauwers-Cances V., et al. Understanding the role of hyperdiploidy in myeloma prognosis: Which trisomies really matter? Blood. 2015; 126(25): 2713–9. DOI: 10.1182/blood-2015-06-650242.

27. Boyd K.D., Ross F.M., Tapper W.J., et al. The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy. Genes Chromosomes Cancer. 2011; 50(10): 765–74. DOI: 10.1002/gcc.20899.

28. Boyd K.D., Ross F.M., Walker B.A., et al. Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival. Clin Cancer Res. 2011; 17(24): 7776–84. DOI: 10.1158/1078-0432.CCR-11-1791.

29. Hebraud B., Leleu X., Lauwers-Cances V., et al. Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: The IFM experience on 1195 patients. Leukemia. 2014; 28(3): 675–9. DOI: 10.1038/leu.2013.225.

30. Leone P.E., Walker B.A., Jenner M.W., et al. Deletions of CDKN2C in multiple myeloma: Biological and clinical implications. Clin Cancer Res. 2008; 14(19): 6033–41. DOI: 10.1158/1078-0432.CCR-08-0347.

31. Chang H., Qi X., Jiang A., et al. 1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma. Bone Marrow Transplant. 2010; 45(1): 117–21. DOI: 10.1038/bmt.2009.107.

32. Weinhold N., Kirn D., Seckinger A., et al. Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma. Haematologica. 2016; 101(3): 116–9. DOI: 10.3324/haematol.2015.136929.

33. Fonseca R., Oken M.M., Greipp P.R. Eastern Cooperative Oncology Group Myeloma Group. The t(4;14)(p16.3;q32) is strongly associated with chromosome 13 abnormalities in both multiple myeloma and monoclonal gammopathy of undetermined significance. Blood. 2001; 98(4): 1271–72. DOI: 10.1182/blood.v98.4.1271.

34. Zubasheva E.I., Obukhova T.N., Andreeva N.E., et al. Prognostic significance of chromosome aberrations in multiple myeloma. Gematologiya i Transfusiologiya. 2008; 53(6): 31–5 (In Russian).

35. Chiecchio L., Protheroe R.K.M., Ibrahim A.H., et al. Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma. Leukemia. 2006; 20(9): 1610–7. DOI: 10.1038/sj.leu.2404304.

36. Terpos E., Katodritou E., Roussou M., et al. High serum lactate dehydrogenase adds prognostic value to the international staging system even in the era of novel agents. Eur J Haematol. 2010; 85: 114–9. DOI: 10.1111/j.1600-0609.2010.01466.x.

37. Fonseca R., Bergsagel P.L., Drach J., et al. International Myeloma Working Group. International Myeloma Working Group molecular classification of multiple myeloma: spot light review. Leukemia. 2009; 23(12): 2210–22. DOI: 10.1038/leu.2009.174.

38. Gaballa S., Saliba R.M., Srour S., et al. Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant. Am J Hematol. 2016; 91(10): E442–7. DOI: 10.1002/ajh.24487.

39. Walker B.A., Wardell C.P., Brioli A., et al. Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients. Blood Cancer J. 2014; 4(3): 1–7. DOI: 10.1038/bcj.2014.13.

40. Sekiguchi N., Ootsubo K., Wagatsuma M., et al. Impact of C-Myc generelated aberrations in newly diagnosed myeloma with bortezomib/dexamethasone therapy. Int J Hematol. 2014; 99(3): 288–95. DOI: 10.1007/s12185-014-1514-1.

41. Chang H., Sloan S., Li D., et al. The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant. Br J Haematol. 2004; 125(1): 64–8. DOI: 10.1111/j.1365-2141.2004.04867.x.